Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co‐adsorption of ALF or ALFQ adjuvant to the aluminum‐antigen complex

&NA; Aluminum salts have been used as vaccine adjuvants for >50 years, and they are currently present in at least 146 licensed vaccines worldwide. In this study we examined whether adsorption of Army Liposome Formulation (ALF) to an aluminum salt that already has an antigen adsorbed to it might result in improved immune potency of the aluminum‐adsorbed antigen. ALF is composed of a family of anionic liposome‐based adjuvants, in which the liposomes contain synthetic phospholipids having dimyristoyl fatty acyl groups, cholesterol and monophosphoryl lipid A (MPLA). For certain candidate vaccines, ALF has been added to aluminum hydroxide (AH) gel as a second adjuvant to form ALFA. Here we show that different methods of preparation of ALF changed the physical structures of both ALF and ALFA. Liposomes containing the saponin QS21 (ALFQ) have also been mixed with AH to form ALFQA as an effective combination. In this study, we first adsorbed one of two different antigens to AH, either tetanus toxoid conjugated to 34 copies of a hapten (MorHap), which has been used in a candidate heroin vaccine, or gp140 protein derived from the envelope protein of HIV‐1. We then co‐adsorbed ALF or ALFQ to the AH to form ALFA or ALFQA. In each case, the immune potency of the antigen adsorbed to AH was greatly increased by co‐adsorbing either ALF or ALFQ to the AH. Based on IgG subtype and cytokine analysis by ELISPOT, ALFA induced predominately a Th2‐type response and ALFQ and ALFQA each induced more balanced Th1/Th2 responses. Graphical abstract Figure. No Caption available.

[1]  M. Kundi New hepatitis B vaccine formulated with an improved adjuvant system , 2007, Expert Review of Vaccines.

[2]  T. Kündig,et al.  Immunity in response to particulate antigen-delivery systems. , 2005, Advanced drug delivery reviews.

[3]  Z. Beck,et al.  Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. , 2015, Biochimica et biophysica acta.

[4]  M. Storgaard,et al.  Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. , 2014, The Journal of infectious diseases.

[5]  Harm HogenEsch,et al.  Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants , 2013, Front. Immun..

[6]  Arnaud M. Didierlaurent,et al.  AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1 , 2009, The Journal of Immunology.

[7]  Christopher Exley,et al.  The immunobiology of aluminium adjuvants: how do they really work? , 2010, Trends in immunology.

[8]  J. R. Turner Efficacy , 2020, Encyclopedia of Behavioral Medicine.

[9]  G. Matyas,et al.  Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines , 2012, Expert review of vaccines.

[10]  J. Tschopp,et al.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[11]  I. Carletti,et al.  Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years , 2009, Human vaccines.

[12]  C. Silverman,et al.  Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Reed,et al.  Adjuvants for human vaccines. , 2012, Current opinion in immunology.

[14]  G. Leroux-Roels,et al.  A hepatitis B vaccine formulated with a novel adjuvant system. , 2000, Vaccine.

[15]  N. Andrews,et al.  Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females , 2017, Human vaccines & immunotherapeutics.

[16]  Paul Richman,et al.  Aluminum salts in vaccines--US perspective. , 2002, Vaccine.

[17]  J. Bryan Developing an HPV vaccine to prevent cervical cancer and genital warts. , 2007, Vaccine.

[18]  M. McElrath,et al.  Selection of potent immunological adjuvants for vaccine construction. , 1995, Seminars in cancer biology.

[19]  P. Burkhard,et al.  Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants. , 2017, Vaccine.

[20]  G. Keating,et al.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. , 2003, Drugs.

[21]  Dexiang Chen,et al.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. , 2011, Journal of pharmaceutical sciences.

[22]  N. Garçon,et al.  Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems , 2011, Expert review of vaccines.

[23]  N. Waters,et al.  Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. , 2017, Vaccine.

[24]  D. Riesner,et al.  Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases* , 2011, The Journal of Biological Chemistry.

[25]  M. Amiji,et al.  The impact of size on particulate vaccine adjuvants. , 2014, Nanomedicine.

[26]  S. Hem,et al.  Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation , 2007, Expert review of vaccines.

[27]  Z. Beck,et al.  Liposomal adjuvants for human vaccines , 2016, Expert opinion on drug delivery.

[28]  D. O'hagan,et al.  Designing and building the next generation of improved vaccine adjuvants. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[29]  E. Elinav,et al.  Integration of Innate Immune Signaling. , 2016, Trends in immunology.

[30]  Z. Beck,et al.  Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. , 2015, Vaccine.

[31]  J. Muderhwa,et al.  Oil-in-water liposomal emulsions for vaccine delivery. , 2003, Methods in enzymology.

[32]  N. Michael,et al.  Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant , 2017, npj Vaccines.

[33]  R. Coffman,et al.  Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.

[34]  J. Deschamps,et al.  Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. , 2015, Bioconjugate chemistry.